OncoMatch/Clinical Trials/NCT04700527
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Is NCT04700527 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Short Chain Fatty Acid and Tapioca Flour for toxicity.
Treatment: Short Chain Fatty Acid · Tapioca Flour — The purpose of this study is to assess and compare GI toxicity from RT between subjects who receive therapeutic SCFA and those who receive placebo, in hopes of identifying a safe, low-cost therapeutic to reduce GI toxicity from therapeutic or environmental radiation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: abdominopelvic radiotherapy
Prior abdominopelvic RT to a region with anticipated direct overlap with the present planned course of RT
Lab requirements
Kidney function
Creatinine clearance < 50 mL/min [excluded]
Cardiac function
Congestive heart failure [excluded]
Creatinine clearance < 50 mL/min [excluded]; Congestive heart failure [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Flora Danquah · Chapel Hill, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04700527 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior abdominopelvic radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages